AXP
0.018
38.5%
ZNO
0.093
-40%
APL
0.15
36.4%
RAN
0.002
-33.3%
TMKDD
0.15
36.4%
TPG
3.8
-32.1%
BIT
0.004
33.3%
CMG
0.13
-23.5%
GAS
0.03
30.4%
RWD
0.039
-20.4%
MTB
0.014
27.3%
8IH
0.018
-18.2%
CAV
0.005
25%
NVA
1.195
-17.6%
FBM
0.064
23.1%
AKN
0.005
-16.7%
EGR
0.545
22.5%
AVL
0.01
-16.7%
HAR
0.165
22.2%
IPT
0.005
-16.7%
RCR
0.017
21.4%
SHP
0.03
-16.7%
OM1
0.023
21.1%
VAR
0.005
-16.7%
HE8
0.012
20%
RXL
0.38
-16.5%
LGM
0.25
19%
REC
0.016
-15.8%
IS3
0.019
18.8%
BLG
0.011
-15.4%
KFM
0.09
18.4%
IRI
0.305
-15.3%
CHR
0.1
17.6%
AVE
0.006
-14.3%
NXD
0.41
17.1%
BNL
0.006
-14.3%
AHK
0.525
16.7%
M4M
0.006
-14.3%
MGU
0.007
16.7%
PLC
0.006
-14.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AGN on track for Phase 2 trials during CY24

Argenica Therapeutics (ASX:AGN) has completed the manufacturing of the ARG-007 drug required for Phase 2 clinical trials. The finalised, sterile drug product manufacturing will be completed by the end of the year keeping the Argenica on track for first patient dosing during Q1 CY24 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231214/pdf/05yjzbqmnd1b00.pdf $AGN #Phase2 #ClinicalTrials #shorts